blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1648494

EP1648494 - Anti-angiogenetic agent and its use in cancer treatment [Right-click to bookmark this link]
Former [2006/17]NOVEL ANTI-ANGIOGENETIC AGENT AND ITS USE, IN PARTICULAR IN CANCER TREATMENT
[2011/24]
StatusNo opposition filed within time limit
Status updated on  28.12.2012
Database last updated on 22.01.2025
Most recent event   Tooltip18.07.2014Lapse of the patent in a contracting state
New state(s): HU		published on 20.08.2014  [2014/34]
Applicant(s)For all designated states
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE -CNRS-
3, rue Michel-Ange
75794 Paris Cedex 16 / FR
For all designated states
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
101, rue de Tolbiac
75654 Paris Cédex 13 / FR
[N/P]
Former [2006/17]For all designated states
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
3, rue Michel Ange
75794 Paris Cedex 16 / FR
For all designated states
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
101, rue de Tolbiac
75654 Paris Cédex 13 / FR
Inventor(s)01 / PLOUET, Jean
94, rue de l'Amiral Mouchez
F-75014 Paris / FR
02 / LAURENT-BEUBRY, Maryvonne
4bis, rue Gambetta
F-91300 Massy / FR
03 / MARTINERIE-KRYCEVE, Cécile
153, chemin de la Hunière
F-91120 Palaiseau / FR
 [2006/17]
Representative(s)Grosset-Fournier, Chantal Catherine
Grosset-Fournier & Demachy
54, rue Saint-Lazare
75009 Paris / FR
[N/P]
Former [2012/08]Grosset-Fournier, Chantal Catherine
Grosset-Fournier & Demachy 54, rue Saint-Lazare
75009 Paris / FR
Former [2006/17]Grosset-Fournier, Chantal Catherine
Grosset-Fournier & Demachy, 54, rue Saint-Lazare
75009 Paris / FR
Application number, filing date04786012.730.07.2004
[2006/17]
WO2004FR02050
Priority number, dateFR2003000950601.08.2003         Original published format: FR 0309506
[2006/17]
Filing languageFR
Procedural languageFR
PublicationType: A2 Application without search report
No.:WO2005011725
Date:10.02.2005
Language:FR
[2005/06]
Type: A2 Application without search report 
No.:EP1648494
Date:26.04.2006
Language:FR
The application published by WIPO in one of the EPO official languages on 10.02.2005 takes the place of the publication of the European patent application.
[2006/17]
Type: B1 Patent specification 
No.:EP1648494
Date:22.02.2012
Language:FR
[2012/08]
Search report(s)International search report - published on:EP09.09.2005
ClassificationIPC:A61K38/18, A61P35/00, A61P17/00, A61P19/02, A61P27/02, A61P37/06
[2006/17]
CPC:
A61K38/1754 (EP,US); A61P17/00 (EP); A61P19/02 (EP);
A61P27/02 (EP); A61P29/00 (EP); A61P3/10 (EP);
A61P35/00 (EP); A61P37/00 (EP); A61P37/06 (EP);
A61P9/00 (EP); A61P9/10 (EP) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IT,   LI,   LU,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2006/17]
TitleGerman:Anti-angiogenetisches Mittel und seine Verwendung bei der Krebsbehandlung[2011/24]
English:Anti-angiogenetic agent and its use in cancer treatment[2011/24]
French:Agent anti-angiogenique et son utilisation dans le cadre du traitement des cancers[2011/24]
Former [2006/17]NEUES ANTI-ANGIOGENETISCHES MITTEL UND SEINE VERWENDUNG, INSBESONDERE BEI DER KREBSBEHANDLUNG
Former [2006/17]NOVEL ANTI-ANGIOGENETIC AGENT AND ITS USE, IN PARTICULAR IN CANCER TREATMENT
Former [2006/17]NOUVEL AGENT ANTI-ANGIOGENIQUE ET SON UTILISATION, NOTAMMENT DANS LE CADRE DU TRAITEMENT DES CANCERS
Entry into regional phase31.01.2006National basic fee paid 
31.01.2006Designation fee(s) paid 
31.01.2006Examination fee paid 
Examination procedure31.01.2006Examination requested  [2006/17]
04.07.2006Despatch of a communication from the examining division (Time limit: M06)
04.01.2007Reply to a communication from the examining division
25.02.2008Despatch of a communication from the examining division (Time limit: M08)
10.10.2008Reply to a communication from the examining division
01.03.2011Despatch of a communication from the examining division (Time limit: M04)
15.04.2011Reply to a communication from the examining division
12.09.2011Communication of intention to grant the patent
10.01.2012Fee for grant paid
10.01.2012Fee for publishing/printing paid
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  04.07.2006
Opposition(s)23.11.2012No opposition filed within time limit [2013/05]
Fees paidRenewal fee
26.07.2006Renewal fee patent year 03
31.07.2007Renewal fee patent year 04
30.07.2008Renewal fee patent year 05
28.07.2009Renewal fee patent year 06
29.07.2010Renewal fee patent year 07
29.07.2011Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Licence(s)ID:01 01/exclusive
For:AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR
Licencee:SISENE
Faculté de Médecine Cochin Port Royal
24 Rue Faubourg Saint Jacques
75014 Paris / FR
Date:12.01.2012
[2012/12]
Lapses during opposition  TooltipHU30.07.2004
AT22.02.2012
CY22.02.2012
CZ22.02.2012
DK22.02.2012
EE22.02.2012
FI22.02.2012
IE22.02.2012
PL22.02.2012
RO22.02.2012
SE22.02.2012
SI22.02.2012
SK22.02.2012
TR22.02.2012
BG22.05.2012
GR23.05.2012
MC31.07.2012
[2014/34]
Former [2014/21]AT22.02.2012
CY22.02.2012
CZ22.02.2012
DK22.02.2012
EE22.02.2012
FI22.02.2012
IE22.02.2012
PL22.02.2012
RO22.02.2012
SE22.02.2012
SI22.02.2012
SK22.02.2012
TR22.02.2012
BG22.05.2012
GR23.05.2012
MC31.07.2012
Former [2013/33]AT22.02.2012
CY22.02.2012
CZ22.02.2012
DK22.02.2012
EE22.02.2012
FI22.02.2012
IE22.02.2012
PL22.02.2012
RO22.02.2012
SE22.02.2012
SI22.02.2012
SK22.02.2012
BG22.05.2012
GR23.05.2012
MC31.07.2012
Former [2013/11]AT22.02.2012
CY22.02.2012
CZ22.02.2012
DK22.02.2012
EE22.02.2012
FI22.02.2012
IE22.02.2012
PL22.02.2012
RO22.02.2012
SE22.02.2012
SI22.02.2012
SK22.02.2012
GR23.05.2012
MC31.07.2012
Former [2013/07]AT22.02.2012
CY22.02.2012
CZ22.02.2012
DK22.02.2012
EE22.02.2012
FI22.02.2012
IE22.02.2012
PL22.02.2012
RO22.02.2012
SE22.02.2012
SI22.02.2012
SK22.02.2012
GR23.05.2012
Former [2012/50]CY22.02.2012
CZ22.02.2012
DK22.02.2012
EE22.02.2012
FI22.02.2012
IE22.02.2012
PL22.02.2012
RO22.02.2012
SE22.02.2012
SI22.02.2012
SK22.02.2012
GR23.05.2012
Former [2012/49]CY22.02.2012
CZ22.02.2012
DK22.02.2012
EE22.02.2012
FI22.02.2012
IE22.02.2012
PL22.02.2012
RO22.02.2012
SE22.02.2012
SI22.02.2012
GR23.05.2012
Former [2012/48]CY22.02.2012
EE22.02.2012
FI22.02.2012
IE22.02.2012
SE22.02.2012
GR23.05.2012
Former [2012/47]CY22.02.2012
FI22.02.2012
IE22.02.2012
GR23.05.2012
Former [2012/41]CY22.02.2012
FI22.02.2012
GR23.05.2012
Former [2012/37]FI22.02.2012
GR23.05.2012
Former [2012/36]GR23.05.2012
Cited inInternational search[PX]EP1382347  (UNIV PARIS 7 DENIS DIDEROT [FR]) [PX] 1-9 * page 4, line 19 - line 22; figures 1A,1B; claim 12 ** page 5, line 30 - line 32 *;
 [Y]  - PERBAL BERNARD ET AL, "The C-terminal domain of the regulatory protein NOVH is sufficient to promote interaction with fibulin 1C: A clue for a role of NOVH in cell-adhesion signaling", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (19990202), vol. 96, no. 3, ISSN 0027-8424, pages 869 - 874, XP002322020 [Y] 1-9 * abstract * * page 869, column R, paragraph L - page 870, column L, paragraph 2; figure 1 * * page 873, column R, paragraph 3 * * page 874, column L, paragraph L *

DOI:   http://dx.doi.org/10.1073/pnas.96.3.869
 [Y]  - M.L. IRUELA-ARISPE ET AL., "INHIBITION OF ANGIOGENESIS BY THROMBOSPONDIN-1 IS MEDIATED BY 2 INDEPENDENT REGIONS WITHIN THE TYPE 1 REPEATS", CIRCULATION, AMERICAN HEART ASSOCIATION, DALLAS, TX, US, (19990928), vol. 100, no. 13, ISSN 0009-7322, pages 1423 - 1431, XP000923386 [Y] 1-9 * page 1424, column R, paragraph 2 - page 1429, column L, paragraph 2; figures 4,5 *
 [Y]  - INOKI ISAO ET AL, "Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis", FASEB JOURNAL, (20010214), pages 1 - 27, URL: http://www.fasebj.org/cgi/reprint/01-0332fjev1?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=inoki&searchid=1111582791442_665&stored_search=&FIRSTINDEX=0&volume=16&issue=2&journalcode=fasebj, (20050321), XP002321942 [Y] 1-9 * page 7, paragraph 3 - page 9, paragraph 3; figures 1-10 *
 [DY]  - INOKI ISAO ET AL, THE FASEB JOURNAL, (200202), vol. 16, no. 2, ISSN 1530-6860, pages 219 - 221 [DY] 1-9 * the whole document *
 [A]  - N. GUPTA ET AL., "INHIBITION OF GLIOMA CELL GROWTH AND TUMORIGENIC POTENTIAL BY CCN3 (NOV)", JOURNAL OF CLINICAL PATHOLOGY: MOLECULAR PATHOLOGY, BMJ PUBLISHING GROUP, LONDON, GB, (200110), vol. 54, no. 5, ISSN 1366-8714, pages 293 - 299, XP008010748 [A] 1-9 * page 298, column L, paragraph 2 * * page 298, column R, line 5 - line 9 *

DOI:   http://dx.doi.org/10.1136/mp.54.5.293
 [DA]  - C.G. LIN ET AL., "CCN3 (NOV) is a novel angiogenic regulator of the CCN protein family.", JOURNAL OF BIOLOGICAL CHEMISTRY, BALTIMORE, MD, US, (20030627), vol. 278, no. 26, pages 24200 - 24208, XP002272895 [DA] 1-9 * the whole document *

DOI:   http://dx.doi.org/10.1074/jbc.M302028200
 [A]  - L.F. LAU ET AL., "The CCN family of angiogenic regulators: the integrin connection.", EXPERIMENTAL CELL RESEARCH, (1999), vol. 248, pages 44 - 57, XP002272896 [A] 1-9 * page 45, column L, paragraph 3 * * page 45, column R, paragraph L - page 47, column L, paragraph 2; figures 1,2 *

DOI:   http://dx.doi.org/10.1006/excr.1999.4456
by applicant   - BORK P, "The modular architecture of a new family of growth regulators related to connective tissue growth factor", FEBS LETT., (1993), vol. 327, pages 125 - 130
    - BRADHAM DM, IGARASHI A, POTTER RL, GROTENDORST GR, "Connective tissue growth factor: a cysteine-rich.mitogen secreted by human vascular endothelial cells is related to the SRC-induced immediate early gene product CEF-10", J CELL BIOL., (1991), vol. 114, pages 1285 - 1294
    - BRIGSTOCK DR, "The connective tissue growth factor/cysteine-rich 61/ nephroblastoma overexpressed (CCN) family", ENDOCRINE REV., (1999), vol. 20, pages 189 - 206
    - BROOKS PC, CLARK RA, CHERESH DA, "Requirement of vascular integrin alpha v beta 3 for angiogenesis", SCIENCE, (1994), vol. 264, pages 569 - 71
    - CELERIER J, CRUZ A, LARNANDE N, GASC JM, CORVOL P, "Angiotensinogen and its cleaved derivatives inhibit angiogenesis", HYPERTENSION, (2002), vol. 39, no. 2, pages 224 - 8
    - CHEVALIER G, YEGER H, MARTINERIE C ET AL., "nov H: Differential expression in developing kidney and in Wilms' tumors", AM J PATHOL., (1998), vol. 152, pages 1563 - 1575
    - HASHIMOTO Y, SHINDO-OKADA N, TANI M ET AL., "Expression of the Elm-1 gene, a novel gene of the CCN (CTGF, Cyr61/CeflO and nov) farnily, suppress in vivo growth and metastasis of K-1735 murine melanoma cells", JEXP MED., (1998), vol. 187, pages 289 - 296
    - HERBST ET AL., J. CLIN. ONCOI., (2002), vol. 20, pages 3804 - 3814
    - INOKI I, SHIOMI T, HASHIMOTO G, ENOMOTO H, NAKAMURA H, MAKINO K., IKEDA E, TAKATA S, KOBAYASHI K, OKADA Y, "Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis", FASEB J., (2002), vol. 16, no. 2, pages 219 - 21
    - JAIN RK, SCHLENGER K, HOCKEL M, YUAN F, "Quantitative angiogenesis assays: progress and problems", NAT MED., (1997), vol. 3, no. 11, pages 1203 - 8
    - JOLIOT V, MARTINERIE C, DAMBRINE G ET AL., "Proviral rearrangements and overexpression of a new cellular gene (nov) in myeloblastosis-associated virus type 1- induced nephroblastomas", MOL CELL BIOL., (1992), vol. 12, pages 10 - 21
    - KEARNEY JF, RADBRUCH A, LIESEGANG B, RAJEWSKY K, "A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines", J IMMUNOL., (1979), vol. 123, pages 1548 - 50
    - KOCIALKOWSKI SY, H. KINGDOM, J. PERBAL, B. SCHOFIELD, PN, "Expression of the human NOV gene in first trimester fetal tissues", ANAT EMBRYOL., (2001), vol. 203, pages 417 - 427
    - KUMAR S, HAND AT, CONNOR JR ET AL., "Identification and cloning of a Connective tissue growth factor-like cDNA from human osteoblasts encoding a novel regulator of osteoblast functions", J BIOL CHEM., (1999), vol. 274, pages 17123 - 17131
    - LAU L, NATHANS D, "Expression of a set of growth-regulated immediate early genes in BALB/c 3T3 cells: coordinate regulation with c-fos or c-myc", PROC NATL ACADSCI USA, (1985), vol. 84, pages 1182 - 1186
    - LIN CJ, LEU S-J, CHEN N, TEBEAU CM, LIN S-X, YEUNG C-H, LAU LJ, "CCN3 (NOV) is a novel angiogenic regulator of the CCN protein family", J BIOL. CHEM., (2003), vol. 278, pages 24200 - 24208
    - MARTINERIE C, GICQUEL C, LOUVEL A, LAURENT M, SCHOFIELD P, LEBOUC Y, "Altered expression of NovH is asociated with human adrenocortical tumorigenesis", JCEM., (2001), vol. 86, pages 3929 - 3940
    - MARTINERIE C, HUFF V, JOUBERT I ET AL., "Structural analysis of the human nov proto-oncogene and expression in Wilms tumor", ONCOGENE, (1994), vol. 9, pages 2729 - 2732
    - MARTINERIE C, PERBAL B, "Expression of a gene encoding a novel IGF binding protein in human tissues", C R ACAD SCI PARIS., (1991), vol. 313, pages 345 - 351
    - O'REILLY ET AL., CELL, (1997), vol. 88, pages 277 - 285
    - ORTéGA N, HUTCHINGS H, PLOUëT J, "Signal relays in the VEGF system", FRONT. BIOSC., (1999), vol. 4, pages D141 - D152
    - PENNICA D, SWANSON TA, WELSH JW ET AL., "WISP genes are members of the connective tissue growth factor family that are up-regulated in human colon tumors", PROC NATL ACAD SCI., (1998), vol. 95, pages 14717 - 14722
    - PERBAL B, MARTINERIE C, SAINSON R, WERNER M, HE B, ROIZMAN B, "The C-terminal domain of the regulatory protein NOVH is sufficient to promote interaction with fibulin 1C: a clue for a role of NOVH in cell- adhesion signaling", PROC NATL ACAD SCI USA., (1999), vol. 96, pages 869 - 874
    - PLOUëT J, MORO F, COLDEBOEUFN, BERTAGNOLLI S, CLAMENS S, BAYARD F, "Extracellular cleavage of the vascular endothelial growth factor 189 aa form by urokinae is required for its mitogenic activity", J. BIOL. CHEM., (1997), vol. 272, pages 13390 - 13396
    - SNAITH M, NATARAJAN D, TAYLOR L ET AL., "Genomic structure and chromosomal mapping of the mouse nov gene", GENOMICS, (1996), vol. 38, pages 425 - 428
    - THIBOUT H, MARTINERIE C, CREMINON C, GODEAU F, BOUDOU P, LE BOUC Y, LAURENT M, "Characterization of NOVH in biological fluids: an enzyme immuno assay for the quantification of NOVH in sera from patients with diseases of the adrenal gland and of the nervous system", J CLIN ENDOCRINOL METAB., (2003), vol. 88, no. 1, pages 327 - 336
    - YING Z, LING ML, "Isolation and characterization of xnov, a Xenopus laevis ortholog of the chicken nov gene", GENE, (1996), vol. 17, no. 1, pages 243 - 248
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.